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Abstract
Background: In the broader spectrum of back pain, inflammatory back pain (IBP) is a symptom that may indicate
axial spondyloarthritis (SpA). The objectives of this study were to determine the frequency of current IBP, as a
hallmark sign of possible axial SpA, in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA) and other
SpA and to compare self-reported health between the groups with current IBP.
Methods: Five-thousand seven hundred seventy one patients identified in the regional healthcare register of the
most southern county of Sweden, diagnosed at least once by a physician (based on ICD-codes) with any type of
SpA in 2003–2007, were sent a postal survey in 2009. Patients with current IBP were identified, based on self-
reported back pain ≥3 months in the preceding year and fulfilling the Berlin criteria for IBP. The frequencies of
IBP in AS, PsA and other SpA (including the remaining subgroups of SpA) were determined, and the groups were
compared with regard to patient reported outcome measures (PROMs).
Results: The frequency and proportion of patients with current IBP in AS, PsA and other SpA were 319 (43 %), 409
(31 %) and 282 (39 %) respectively, within the responders to the survey (N = 2785). The proportion was statistically
higher in AS, compared to PsA (p < 0.001), but not for AS compared to other SpA (p = 0.112). PsA and other SpA,
with current IBP, had similar (BASFI, EQ-5D, patients global assessment, fatigue, spinal pain) or worse (BASDAI) PROMs,
compared to AS with current IBP. PsA with current IBP received pharmacological, anti-rheumatic, treatment more
frequently than AS with current IBP, while AS and other SpA received treatment to a similar degree.
Conclusion: The proportion of patients with current IBP was substantial in all three groups and health reports in the
non-AS groups were similar or worse compared to the AS group supporting the severity of IBP in these non-AS SpA
groups. These findings may indicate a room for improvement concerning detection of axial disease within different
subtypes of non-AS SpA, and possibly also for treatment.
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Background
The spondyloarthritis (SpA) group includes a number of
similar inflammatory diseases, with varying degrees of in-
flammation in peripheral joints, entheses, spine, gut, skin,
eyes and other organs. In a clinical setting SpA-disease is
often categorized through its most prominent feature, e.g.
psoriatic arthritis (PsA), SpA associated with inflammatory
bowel disease (IBD), reactive arthritis (ReA) or axial SpA.
In axial SpA the most prominent feature is chronic back
pain, usually accompanied with symptoms of inflamma-
tory back pain (IBP) and often with signs of inflammation
in the sacroiliac joints and spine [1, 2]. Axial SpA having
resulted in radiographically detectible sacroilitis is clinic-
ally diagnosed as ankylosing spondylitis (AS) [3], while
axial SpA without radiographic sacroilitis may be classi-
fied as non-radiographic axial-SpA, according to the
“Assessment of SpondyloArthritis” (ASAS) criteria for
axial SpA[1].AS is known to be more common in men
and non-radiographic axial SpA in women, and the pro-
gression rate from non-radiographic axial SpA to AS is
considered to be around 10–12 % over 2 years [1].
The most common presentation of axial SpA is IBP
[2], wherefore this is one of the key symptoms that are
asked for in a clinical setting, when trying to identify pa-
tients with axial SpA. However, neither the modified
New York criteria for AS [4] nor the current ASAS cri-
teria for axial SpA[5] includes past or present IBP as a
compulsory feature. In fact, both the sensitivity and the
specificity of IBP for axial SpA, classified according to
the ASAS-criteria in the setting of established axial SpA
or chronic back pain, is 70–80 % [6, 7], illustrating the
fact that not all patients with axial SpA have IBP and
that axial disease activity may vary over time [8].
The frequency and disease activity of axial disease in
other subtypes of SpA, where chronic back pain is not
the predominant symptom, i.e. patients not referred to a
rheumatologist due to back pain or patients with a pre-
dominantly peripheral disease, is less studied. In one
study, comparisons between patients with AS, PsA and
SpA associated with IBD (all with radiographic sacroili-
tis) indicated no significant differences with regard to
axial disease activity[9]. This comparison was however
limited by excluding all forms of non-radiographic axial
disease and by only focusing on patients with typical
radiographic findings of sacroilitis. In patients with PsA
attending a rheumatology clinic the frequency of IBP has
been described to be as high as 49 % [10], and one recent
study demonstrated a high frequency of IBP among young
patients with cutaneous psoriasis (17 %) [11], which may
indicate that axial disease is more common in psoriasis
than previously thought. In conclusion, there is relatively
little knowledge of how common symptoms of IBP are
among different subtypes of SpA and how this is reflected
in patient-perceived disease activity.
Our objectives in this cross-sectional, population based,
study was to firstly, assess the proportion of patients with
IBP within different subtypes of SpA, and secondly, to
compare self-reported disease activity between the groups
with IBP, in order to explore possible differences with re-
gard to self-perceived severity. The study is based on a
well-established and validated cohort of clinically diag-
nosed SpA patients, the SpAScania cohort.
Methods
Setting
This cross-sectional study was performed in the county
of Skåne in southern Sweden, with a population of 1.2
million. Population-based healthcare registers were used
to identify cases with SpA in Skåne, to whom a postal
survey was sent in 2009.
Data sources
The registers used in this study were the Skåne Health
Care Register (SHCR) [12] and the Prescribed Drugs
Register. All data in the registers were linked to the pa-
tients’ personal identification numbers (PIN), which are
unique identifiers given to all residents in Sweden. The
PIN allows the information on individuals in different
registers to be cross-linked [13]. Additional file 1: Table S1
presents the ICD-10 (International Classification of Dis-
eases) and ATC-codes (Anatomical Therapeutic Chemical
codes) [14] that were used in the study.
The SHCR contains information from every patient visit
to healthcare providers included in the national reim-
bursement system (the majority). Outpatient, inpatient,
primary, and specialized care providers are all included.
The data collected include disease codes, according to the
Swedish version of the ICD-10 [15] (up to eight codes/
visit), dates of visit/admission/discharge, and other admin-
istrative data.
The Prescribed Drugs Register collects information on
all drugs dispensed in Sweden since July 2005: date of
prescription/dispensation and the prescribed dose. The
drugs are classified according to the ATC classification
system [14].
Ethical approval
The Regional Ethical Review Board at Lund University,
Sweden, approved the study (301/2007, 406/2008). In-
formed consent was obtained in compliance with the
Declaration of Helsinki.
Study population
All patients in the SHCR who were ≥15 years of age and
had a healthcare visit to a physician between January 2003
and December 2007 that resulted in an ICD-10 code that
indicated a SpA diagnosis were identified (N = 6799, the
SpAScania cohort). The diagnoses used were those for AS
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(ICD-10 codes M45 and M08.1), undifferentiated SpA/
Sacroilitis (ICD-10 codes M46.0, M46.1, M46.8 and
M46.9), IBD-associated arthritis (ICD-10 codes M07.4
and M07.5), PsA (ICD-10 codes L40.5 and M07.0-3),
and ReA (ICD-10 codes M02.0-2, M02.8–9, M01.2 and
M03.2). The validity of the SpA-diagnoses in the SpAS-
cania cohort have previously been evaluated and found
to be high [12, 16].
In 2009, all of the subjects identified in the procedure
above, ≥18 years old, and still living in the county, were
invited to participate in a postal survey (N = 5771). For
the same subjects, the ICD-10 codes for the common
SpA-related disease manifestations (IBD, psoriasis, and
anterior uveitis), registered at a visit to a physician in
primary or secondary care between 1998 and 2009 were
extracted from the SHCR (see Additional file 1: Table S1).
The same subjects were also linked to the Prescribed
Drugs Register and the ATC-codes for the following
SpA-related drugs (available for 2005–2009) were col-
lected: the synthetic disease-modifying anti-rheumatic
drugs (sDMARDs): methotrexate and sulphasalazine;
and the tumor necrosis factor alpha inhibitors (TNFi):
etanercept and adalimumab. Infliximab was not included
as this is normally not collected at a pharmacy. The survey
included a number of well-validated generic and disease-
specific patient-reported outcome measures (PROMs):
spinal pain, the patient’s global assessment of back dis-
ease and fatigue, the Bath Ankylosing Spondylitis Activ-
ity Index (BASDAI), the Bath Ankylosing Spondylitis
Functional Index (BASFI) (all measured 0–10, best to
worst, on a numerical rating scale (NRS)) and the European
Quality of Life-5 Dimensions index (EQ-5D; higher score =
better health)[17]. Included were also questions about fre-
quency and duration of back pain; the different features of
inflammatory back pain (IBP); family history of SpA;
current pharmacological treatment and history of psoriasis
and IBD.
Case definitions
AS was defined as having received an ICD-10 code for
AS at ≥1 physician visit during the 2003–2007 study
period. AS is per definition an axial disease and the
ICD-codes for AS in the SHCR have been validated
previously [12]. All the remaining patients in the cohort
had received another clinical diagnosis of SpA, and
never a diagnosis of AS, during the 2003–2007 study
period. This cohort was further divided into psoriatic
arthritis (PsA) (defined as having ever either received a
diagnosis for psoriasis in addition to a diagnosis of SpA,
and/or psoriatic arthritis) and “other-SpA” (having never
received neither a diagnosis of AS nor PsA). Among the
responders to the survey we identified all cases, within
the AS, PsA and “other-SpA” groups, with current IBP,
based on self-reported back pain (pain in the back or
buttocks) for ≥3 months within the last 12 months and
fulfilling the Berlin criteria for IBP. The Berlin criteria
for IBP (rather than the ASAS criteria) were used for
identification of IBP since they may have a higher speci-
ficity and may also perform better in PsA [6, 7, 11].
Reliability analysis
To compare the concordance (and thus indirectly the re-
liability) of data collected by the survey and the registers
(SHCR and the Prescribed Drugs Register), kappa-values
for variables that could be identified in both sources
were calculated. The variables included were current
treatment with methotrexate, sulphasalazine, etanercept,
or adalimumab, and existence of psoriasis or IBD.
Statistical methods
The frequency and proportion of cases with current IBP
was determined for each of the three groups, AS, PsA
and other-SpA, as a total and stratified by sex and 15-
year interval age groups. Between group comparisons
were performed using Fisher’s exact test.
The three groups of AS, PsA and other-SpA, with
current IBP, were compared in terms of levels of PROMs
and frequencies of SpA-related disease manifestations,
and pharmacological treatment by using independent-
sample t-tests and Fisher’s exact test. Due to the multiple
testing performed on the same data set, a Bonferroni cor-
rection was performed to counteract the risk of a type I
error. More specifically comparisons of frequency of
PROMs and pharmacological treatment were done using
a p-value with the cut-off of 0.00125, obtained through a
Bonferroni correction based on a statistical significance of
0.05 and the number of comparisons being 40.
SAS version 9.3 for Windows was used for the aggre-
gation of data and SPSS version 21 for Windows was
used for statistical analyses.
Results
The SpAScania cohort
In total, 5771 individuals received ICD-10 codes for AS,
PsA and other SpA in 2003–2007, were ≥18 years old, and
were living in the county at the time of the survey (2009).
Their mean age was 54.7 years and 53 % were women. Of
these, 1423 (41 % women) had an AS diagnosis and 2280
(57 % women) had PsA (had ever received a diagnosis of
PsA or alternatively any other non-AS SpA diagnosis in
combination with a diagnosis of psoriasis) and 2028 (57 %
women) had another SpA diagnosis. Registered data for
six responders and 32 non-responders were incomplete
and data for two additional subjects were missing when
assembling the data-sets, these were excluded from fur-
ther analyses. Complete responses to the questionnaire
were received from 48 % (n = 2785) of recipients. A flow
chart showing the analysis steps is presented in Fig. 1.
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Of the 2785 responders 319 (43 % of the AS group, 43 %
women) had AS with symptoms of current IBP (reported
back pain ≥3 months within the last 12 months and ful-
filled the Berlin criteria for IBP), 409 (31 % of the PsA
group, 68 % women) had PsA with current IBP and 282
(39 % of the other-SpA group, 69 % women) had other-
SpA with current IBP (Table 1) The differences in the pro-
portions with current IBP was statistically significant for
Fig. 1 Flow chart depicting the selection of the SpAScania cohort. Legend: The figure shows the identification of patients with ankylosing
spondylitis (AS), psoriatic arthritis (PsA) and other spondyloarthritis (SpA) in the Skåne Health Care Register, the proportions reporting current
inflammatory back pain (back pain ≥ 3 months within the last 12 months and fulfilling the Berlin criteria for IBP), the response to the
questionnaire, and the subsequent analyses
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Table 1 Frequency and proportion with current inflammatory back pain among AS, PsA and other-SpA. Legend: For each group only data for responders to the postal survey
(N = 2785) are included, stratified first on sex and then on age-groups. Registered data for 6 responders were incomplete and are thus excluded from the study
Ankylosing Spondylitis (AS) N = 744 Psoriatic arthritis (PsA) N = 1310 p-value AS vs PsA Other Spondyloarthritis (SpA) N = 725 p-value AS vs SpA p-value PsA vs SpA
Men (%) 451 (61) 552 (42) <0.001 286 (39) <0.001 0.240
Current IBPa (%) 319 (43) 409 (31)b <0.001 282 (39)c 0.112 0.001
Sex Women N = 293 Men N = 451 Women N = 758 Men N = 552 Women N = 439 Men N = 286
Current IBP N(%) 137 (47) 182 (40) 280 (37) 129 (23) 195 (44) 87 (30)
p-value men vs women 0.111 <0.001 <0.001
Age groups Total Current IBP (%) Total Current IBP (%) Total Current IBP (%)
15–29 42 12 (29) 50 9 (18) 0.319 72 29 (40) 0.231 0.010
30–44 190 82 (43) 241 73 (30) 0.006 185 74 (40) 0.600 0.040
45–59 243 126 (52) 463 172 (37) <0.001 222 96 (43) 0.077 0.133
60–74 226 86 (38) 464 133 (29) 0.015 198 64 (32) 0.224 0.354
>75 43 13 (30) 92 22 (24) 0.303 48 19 (40) 0.519 0.077
All p-values are based on Fisher’s exact test
aIBP = inflammatory back pain, according to the Berlin criteria
bProportion of IBP in psoriatic arthritis compared to ankylosing spondylitis p < 0.001













AS and other-SpA compared to PsA but not for AS com-
pared to other-SpA. The occurrence of IBP was highest in
the age-group 45–59, where the difference between AS
and PsA was also most pronounced, and decreased after
the age of 60. The proportions with IBP were, further-
more, overall higher in women compared to men, al-
though it reached statistical significance only in other-SpA
and PsA, but not in AS. (Table 1).
PROMs and pharmacological treatment
All PROMs (spinal pain, fatigue, patients global, BASFI
and EQ-5D) were similar in the three groups, apart from
BASDAI which was significantly higher in the PsA group
compared to the AS-group. Using a significance level of
0.05 (without Bonferroni correction) resulted in add-
itional significantly worse scores for PsA compared to
AS for fatigue, and for other-SpA compared to AS for
spinal pain and BASDAI. The mean differences between
AS, PsA and other-SpA in PROMs were however in
absolute numbers small and within a range that is
normally not considered clinically significant [18, 19].
Table 2 summarizes the demographics, SpA features,
PROMs, and pharmacological treatment of the three
groups with current IBP.
PsA, with current IBP, used methotrexate more fre-
quently than the AS and other-SpA groups with current
IBP and etanercept more frequently than the other-SpA
group. No differences in treatment were observed be-
tween AS and other-SpA with current IBP.
Stratifying the groups by sex revealed overall worse re-
sults for all PROMs in women compared to men, but
similar results with regard to differences in men and
women between AS, PsA and other-SpA as those seen in
the overall comparison (Additional file 1: Table S2).
Responders vs. non-responders and reliability analysis
Table 3 shows the differences between the responders and
non-responders in terms of age, gender, SpA diagnosis,
and pharmacological treatment. The non-responders dif-
fered significantly from the responders in that they were
Table 2 Spondyloarthritis features, pharmacological treatment, and PROMs in AS, PsA or other-SpA, with IBP
AS with current IBPa
N = 319
PsA with current IBPa
N = 409




Age 2009, mean (sd)b 54 (13) 57 (13) 53 (15)
Sex, N men (%)b 182 (57) 129 (32) <0.001 87 (31) <0.001 0.860
SpA-related disease, N (%)
Uveitisb 63 (20) 9 (2) <0.001 37 (13) <0.001 <0.001
Psoriasisb 19 (6) 407 (100) <0.001 0
Inflammatory bowel diseaseb 25 (8) 21 (5) 0.901 36 (13) 0.706 0.001
PROMS, mean (95 % Cl)
NRS-spinal painc 5.9 (5.6−6.1) 6.1 (5.9−6.4) 0.068 6.2 (6.0−6.5) 0.037 0.688
NRS-fatiguec 5.8 (5.6−6.1) 6.2 (5.9−6.4) 0.044 6.1 (5.8−6.4) 0.117 0.547
NRS-patients globalc,d 5.2 (4.9−5.4) 5.4 (5.2−5.6) 0.188 5.5 (5.2−5.7) 0.087 0.850
BASDAIc 5.1 (4.8−5.3) 5.7 (5.5−5.8) <0.001 5.5 (5.3−5.8) 0.006 0.530
BASFIc 4.4 (4.2−4.7) 4.8 (4.5−5.0) 0.093 4.4 (4.1−4.7) 0.973 0.093
EQ-5Dc 0.68 (0.66−0.70) 0.65 (0.63−0.67) 0.062 0.67 (0.64−0.69) 0.362 0.421
Treatment, n (%)
Etanerceptb 27 (9) 54 (13) 0.044 15 (5) 0.150 0.001
Adalimumabb 12 (4) 32 (8) 0.027 9 (3) 0.825 0.013
Methotrexateb 37 (12) 151 (37) <0.001 33 (12) 1.000 <0.001
Sulphasalazineb 28 (9) 14 (3) 0.003 24 (9) 1.000 0.006
Abbreviations: AS ankylosing spondylitis, IBD inflammatory bowel disease, NRS numerical rating scale 1–10, BASDAI bath ankylosing spondylitis activity index, BASFI
bath ankylosing spondylitis functional index, PROMs patient-reported outcome measures, IBP inflammatory back pain
Based on 2785 spondyloarthritis patients in the Skåne Health Care Register who responded to a questionnaire, registered data for 6 responders were incomplete
and was thus excluded
*, **AS with current IBP vs. PsA and other-SpA with current IBP, respectively
***PsA with current IBP vs. other-SpA with current IBP
aCurrent IBP: ≥3 months of back pain in the preceding year and fulfilling the Berlin criteria for inflammatory back pain (IBP)
bData from the register (SpA-related disease 1998–2009; treatment 2005–2009)
cData from the survey
dPatient’s global assessment of back disease
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younger, and more likely to have been given a diagnosis of
ReA. Non-responders also were slightly less likely to have
been given diagnoses of AS, undifferentiated SpA, and
PsA. These differences in diagnoses probably explain why
the non-responders also had lower frequencies of use of
sDMARDs and TNF-inhibitors.
To indirectly examine the reliability of the survey and
registry-derived data, kappa-values for variables that
were captured by both data sources were calculated.
The kappa-values (proportion of agreement in paren-
thesis) for SpA disease manifestations and current
treatment were IBD, k = 0.65 (95 %); psoriasis, k = 0.70
(85 %); methotrexate, k = 0.87 (94 %); sulphasalazine, k =
0.91 (97 %); etanercept, k = 0.95 (98 %); and adalimumab,
k = 0.95 (99 %).
Discussion
In this population-based study the frequencies of current
IBP were high in all three groups with AS, PsA and other-
SpA. The proportion of patients afflicted with IBP was
higher for women, compared to men, in PsA and other-
SpA, but equal in AS, and the proportion of cases report-
ing current IBP was highest in AS, yet only 43 %. The
three groups with current IBP had similar levels of self-
perceived health status, reflecting pain, disease activity,
function, and quality of life, which support the validity of
IBP in non-AS SpA groups. However, there was a consist-
ent trend for worse reports in the PsA and other-SpA
groups compared to AS.
In analogy to our study, others have reported that AS
and non-radiographic axial SpA patients attending
rheumatology units have opposite gender distributions
[2, 20, 21]. However, it should be stressed that we are
comparing patients with different subtypes of clinically
diagnosed SpA reporting current IBP, and not axial SpA
according to the ASAS classification criteria, making
comparisons to other studies difficult. The observation
that AS and other axial SpA have similar health status
is supported by a study of consecutive axial SpA pa-
tients at five rheumatology clinics in Germany, where
compared with AS, the non-radiographic axial SpA
phenotype was associated with equivalent self-reported
health status [22]. One possible explanation for the
relatively poor health status in PsA and other-SpA
could be the female predominance in our groups with
IBP in combination with PsA and other-SpA, since it is
known that women in general report worse health sta-
tus than men [23–26]. However, this notion is not sup-
ported by our analyses stratified by sex, were the trends
observed for the PROMs in the gender-mixed groups were
similar for both men and women separately (Additional
file 1: Table S2). Another possible explanation for the
Table 3 Comparison of responders and non-responders, for age, sex, spondyloarthritis diagnosis and pharmacological treatment. Le-
gend: Both responders and non-responders may have received more than one diagnosis or pharmacological treatment during the
respective time frame
Responders (n = 2785)a Non-responders (n = 2986)a p-value
Demographics
Age, median (Q1, Q3) 57 (45, 66) 53 (41, 66) <0.001
Sex, n women (%) 1494 (49) 1551 (51) 0.290
Diagnoses, n (%)
Ankylosing spondylitis 744 (27) 679 (23) 0.001
Psoriatic arthritis 1285 (46) 944 (32) <0.001
Undifferentiated SpA 411 (15) 300 (10) <0.001
Sacroiliitis 157 (6) 209 (7) 0.035
Reactive arthritis 359 (13) 924 (31) <0.001
IBD-associated arthritis 66 (2) 65 (2) 0.659
Spine enthesiopathy 13 (1) 12 (0) 0.842
Psoriatic spondylitis 20 (1) 19 (1) 0.750
Treatment, n (%)
Methotrexate 936 (34) 538 (18) <0.001
Sulphasalazine 297 (11) 159 (5) <0.001
Etanercept 323 (12) 153 (5) <0.001
Adalimumab 168 (6) 94 (3) <0.001
Based on 5771 spondyloarthritis patients in the Skåne Health Care Register who were invited to participate in a survey. All data in the table is based on the health
care registers
Abbreviations: SpA spondyloarthritis, IBD inflammatory bowel disease
a40 subjects had incomplete data and are excluded. Comparisons were performed using independent-sample t-tests and Fisher’s exact test
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poorer health status of these two groups could be insuffi-
cient treatment. However, our study showed that there
were no statistically significant differences in pharmaco-
logical treatment between the AS and the “other-SpA”
group and that the PsA-group was treated more frequently
than the AS group, although non-pharmacological treat-
ment was not accounted for. Since both psoriasis, with and
without arthritis, as well as IBD are indications for treat-
ment with sDMARDs and TNFi in Sweden [27, 28], the
relatively high frequency of pharmacological treatment in
these groups could be related to concurrence of psoriasis,
IBD or peripheral arthritis. On the other hand, the similarly
elevated mean levels of spinal pain, in the AS and non-AS
SpA subgroups with current IBP may support the validity
of IBP and presence of axial disease in these groups. In line
with our results, a recent study based on the NHANES co-
hort found that there was a high frequency (17 %) of IBP
in a group with “self-reported medically diagnosed psoria-
sis” [11]. The fact that only 43 % of patients with AS hade
current IBP may be explained by the fluctuating course of
symptoms, treatment effects and possibly due to decreas-
ing symptoms with higher age.
Some limitations of the study must be discussed.
First, the study setting relied on data from a postal sur-
vey and health care registers, which meant that we
could not retrieve the physicians’ expert opinions re-
garding the existence of axial disease (i.e., the “golden
standard”). Second, the setting and study design also
precluded assessment of biomarkers or imaging, which
are central to both the modified New York criteria for
AS and the ASAS criteria for axial SpA. However, valid-
ation studies based on a review of the clinical records
in our setting have demonstrated a high validity for the
diagnosis of AS on the basis of ICD-10 codes [12, 29]:
over 80 % fulfilled the modified New York criteria,
while 89 % fulfilled one or more of the criteria that are
commonly used to classify patients with SpA. In this
validation process, we also found that over 90 % of
cases identified as undifferentiated SpA fulfilled at least
one of the commonly used classification criteria of SpA,
while only a minority fulfilled the modified New York cri-
teria for AS [29]. Furthermore, a validation study of the
ICD-10 codes for psoriasis in the cohort of the present
study yielded positive predictive values [PPV] of at least
81 % [16]. In our study, the frequencies observed for an-
terior uveitis, psoriasis, and IBD in the AS group were also
similar to those reported in other studies of radiographic
axial SpA [20], also supporting the validity of the diagno-
ses. Based on these validation exercises, and the frequen-
cies of SpA-related disease manifestations, we believe that
the clinical diagnoses of SpA analyzed in this study are
valid. Third, the high rate of non-responders may have af-
fected the results, especially for the group with other-SpA.
The lower frequencies of treatment with sDMARD and
TNFi among non-responders could indicate lower rates of
symptoms in this group, which has to be taken into con-
sideration when trying to generalize our results.
The present study also has several strengths. It is one
of the first population-based studies to assess and com-
pare the frequency of current IBP within different SpA
subtypes and to compare health status. Second, the in-
formation was gathered from several different sources.
In particular, information regarding pharmacological
treatment was gathered from a completely independent
data source. Moreover, analysis of the reliability of our
findings by comparing the data from the survey and the
registers yielded kappa statistics that indicated a “good”
reliability for IBD and psoriasis (k = 0.65 and 0.70, re-
spectively) and a “very good” reliability for the pharma-
cological treatments (k = 0.87–0.95)[30].
Conclusions
To sum up, our results suggest that the frequency of pa-
tients with current IBP is high in AS, PsA and other SpA,
although the proportion is highest for AS. The impact on
health status is, however, similar for patients with AS, PsA
and other SpA with current IBP supporting the validity of
this symptom in non-AS SpA groups. Our data also indi-
cate that in our setting, this may already largely being rec-
ognized by the healthcare services; given that the groups
with PsA and other-SpA received relevant pharmaco-
logical treatments at least as frequently as the AS group.
However, there also appears to be room for improvement
concerning pharmacological and non-pharmacological
treatment, since a high proportion of cases still had symp-
toms and levels of PROMs suggesting an active axial
disease, especially in the group with PsA.
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